CYP3A4 and prostate carcinoma: This conclusion is further supported by the observation that simultaneous combination treatment with a dose of ketoconazole which completely inhibits CYP-3A4 induced tasquinimod metabolism does not suppress tasquinimod's ability to inhibit endothelial “sprouting” in vitro or anti-cancer efficacy against human prostate cancer xenografts in vivo, Figure 5B.